Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[Q]: Amid a scarcity of doctors and public hospitals, India is relying on its mobile telephone network, the second largest in the world with 950 million connections, to reach places where health workers rarely go. “It’s a huge priority for us,” health ministry official Manoj Jhalani told Reuters, adding that the service, advising on vaccinations and vitamin supplements, will launch in eight of the country’s Hindi-speaking states by Aug. 15.”These are the most cost-effective health interventions,” said Jhalani, the supervisor of the project, named ‘Kilkari,’ or “Baby’s Gurgle”, which will tailor its recorded messages to individual stages of pregnancy or the age of a newborn. Poor sanitary conditions and stark poverty prevail in many villages in India, which recorded 50,000 maternal deaths in 2013, when 1.3 million children died before turning five. Preventable hazards such as pneumonia, or poor nutrition, cause most deaths of mothers and babies. Many women give birth at home without access to clean water and toilets, while public medical clinics remain dilapidated and overcrowded. Over the last 18 months, almost 100,000 rural families have signed up for the voice message project, first piloted by the government of the impoverished, but resource-rich, eastern state of Bihar. With India’s health services starved for funds, the mobile phone messages are a cheaper way to spread basic tips on health. Payment delays have led to months of disruption in the traditional system of home visits by health workers to encourage pregnant women to take medicine and follow safety measures. The new project, backed by the Bill and Melinda Gates Foundation and the charity arm of British broadcaster BBC, will make use of a national database to track pregnant women. Another service, Mobile Academy, will also use recorded messages to help train India’s millions of health workers. Health experts welcome the initiatives, but warn such mobile phone campaigns will not be enough to cut mortality rates unless India ramps up health services, particularly in rural areas. “This (mobile services) will have a very marginal effect,” said Dileep Mavalankar, director of the Indian Institute of Public Health in the western state of Gujarat, adding that the health system needed to be strengthened in remote areas.
[A]: India bets on mobiles in battle on maternal, child deaths.


[Q]: CES is allowing space for sex tech companies as a one-year trial. At the show, such companies were scattered throughout the health and wellness section, near startups pitching fitness trackers and infrared saunas. Lora DiCarlo, a startup that pushed for changes after organizers revoked its award, showed off its Osé robotic “personal massager.” It’s one of a dozen companies at the show focused on vibrators, lube dispensers and other sex tech products. Founders of these startups say their products are about empowerment and wellness for women, something they say has often been overlooked in tech. The historically male-dominated tech trade show has received criticism in past years for having an all-male lineup of speakers and for previously allowing scantily clad “booth babes,” fostering a “boys’ club” reputation. Besides allowing sex tech, CES organizers brought in an official “equality partner,” The Female Quotient, to help ensure gender diversity. The Female Quotient, which trains companies in equality practices, will hold a conference for women during the four-day show, which opened Tuesday. “It’s been a process,” said Gary Shapiro, the head of the Consumer Technology Association, which puts on CES. It’s been a longer process for many sex tech companies to convince investors that they are part of a growing trend that has enough customers. Much of the push has come from the startups’ female founders and from younger consumers who talk more openly about sexuality. As with other technologies, some exhibitors including Lora DiCarlo had prominent booths at CES, while others such as the wearable vibrator company Crave were tucked away. Crave’s exhibit included a camper with a “Build-a-Vibe-Workshop,” where attendees could get an engraved vibrator to wear around their neck. Sex tech has existed in some form for decades. But the gates really began to open in 2016, said Andrea Barrica, founder of sex education site O.school. That year, several other “fem tech” companies made progress in areas such as menstruation and menopause. Those paved the way for sex tech to grow and get investors interested. “Larger institutions are starting to take note, all the way from VC firms to large Fortune 100 companies,” said Barrica, who recently published the book “Sextech Revolution: The Future of Sexual Wellness.” Large institutions like CES had no choice but to look at sex tech, she said. The journey hasn’t been easy. Sex tech founders, many of them women, recount being turned down by dozens of investors. They faced decency arguments and entrenched corporate standards that equated them with porn. But investors are becoming more receptive, said Cindy Gallop, a former advertising executive turned sex tech entrepreneur and founder of the website MakeLoveNotPorn. “It’s entirely because of our refusal to allow the business world to put us down,” she said. Founders insist that their devices — ranging from vibrators to lube dispensers to accessories — have effects outside the bedroom. “Sexual health and wellness is health and wellness,” said Lora DiCarlo, CEO and founder of the company of the same name. “It does way more than just pleasure. It’s immediately connected to stress relief, to better sleep, to empowerment and confidence.” DiCarlo’s $290 Osé device has gotten $3 million worth of advance sales, bolstered in part by the attention it received after CES organizers overturned a decision by an independent panel of judges to give the vibrator a prestigious Innovation Honoree Award in the robotics and drone category. The organizers, CTA, told the company it reserved the right to rescind awards for devices deemed “immoral, obscene, indecent, profane or not in keeping with CTA’s image.” DiCarlo and other female founders pushed back for banning them but allowing humanoid sex robots meant to serve men the previous year. Following criticism, CES organizers ultimately  reinstated the award and apologized. A few months later, the show announced policy changes such as a dress code to prevent skimpy outfits and new “Innovation for All” sessions with senior diversity officials. Osé began shipping to customers this month. DiCarlo said the company is planning to introduce new devices, including less expensive options. Sex tech companies still face major barriers to growth. Polly Rodriguez, CEO of sexual wellness company Unbound, said the company is profitable and customers are more open about buying products than they once were. But she said she still faces roadblocks advertising on social media, and many traditional investors snub the company. “Things are better, but there’s just still this genuine fear of female sexuality more broadly within the institutional side of technology,” she said. And while Gallop offered to speak at CES, conference organizers declined, saying sex tech was not a part of its conference programming. ___ AP Business Writer Joseph Pisani contributed to this report. ___ AP’s CES coverage: https://apnews.com/Consumerelectronics
[A]: Sex tech from women-led startups pops up at CES gadget show.


[Q]: The story does a good job of describing the monthly cost ($850) for women who do not have health insurance. The inference is that insurers will cover the cost for others. The story needed to include more information about the study results–in particular, how both the drug and the placebo performed in the trials. As we learn from the NEJM study, the drug reduced pain for about half of the women who took it–but the placebo also reduced pain for about 35% of the women who took it. That’s a good detail to include as it provides a better sense of the drug’s effectiveness. The text does an impressive job of sharing information about the debits of the drug, including bone loss and symptoms of menopause. The double-blind, placebo-controlled trials are described, as are cautions, such as the short-term nature of the research. The reader will find ample information about the unpleasant symptoms of endometriosis. In some areas, it comes close to disease-mongering, when pointing out very rare instances of women needing many surgeries, or a case study of one woman having endometrial tissue in her nose. However, endometriosis is a medical condition, and often under-diagnosed, so we’ll rate this satisfactory. The scientist who led the two trials is clearly identified as such, but his consulting relationship with the company now marketing the drug is not mentioned, nor is the fact that that company, now positioned to benefit from selling the drug, paid for the studies. A number of existing pain-reduction alternatives are mentioned, from hormonal treatments to surgery, and their debits discussed. It would have been helpful to try and articulate how many women find the current alternatives insufficient. The text offers a likely date when this just-approved drug would become available at pharmacies. Although the research report describing the trials was published in The New England Journal of Medicine more than a year ago, this story is pegged to a more useful (to readers) “new event,” the US Food and Drug Administration’s approval of the drug. Abbvie, the company that funded the Stage 3 clinical trials of elagolix (brand name: Orilissa) and will now market the drug, made available an extensive news release on its web site. The Vox story contains a good bit of enterprise reporting and produced a story that is far more clear than the company’s effort.
[A]:
Women with endometriosis experience terrible pain. There’s finally a new treatment.